Cybin Inc., a clinical-stage pharmaceutical company developing next-generation mental health treatments, announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The Company expects its common shares to cease trading on NYSE American at market close on Jan. 4, 2026, and to begin trading on Nasdaq at market open on Jan. 5, 2026, at which time the ticker symbol will change from "CYBN" to "HELP." Cybin will remain listed on Cboe Canada and will also trade under the "HELP" ticker on that exchange beginning Jan. 5, 2026.
The move to Nasdaq represents a significant milestone for Cybin, which is developing novel psychedelic-based treatments for mental health conditions. The company's transition to a more prominent exchange listing could increase visibility among institutional investors and potentially improve liquidity for shareholders. This strategic decision aligns with Cybin's position as a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare through innovative treatment options.
Cybin is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address serious conditions where current therapies are inadequate. The company is also advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder, along with a research pipeline of investigational, 5-HT-receptor focused compounds.
The timing of the exchange transfer coincides with Cybin's clinical development milestones, suggesting the company is positioning itself for potential regulatory approvals and commercial launches. For investors following the psychedelic medicine sector, this move signals Cybin's maturation from early-stage research to late-stage clinical development and potential commercialization. The new "HELP" ticker symbol directly reflects the company's mission to address the large unmet need for people suffering from mental health conditions.
Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom and Ireland, reflecting the global nature of both mental health challenges and psychedelic medicine development. The company's latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN. The full press release regarding the exchange transfer can be viewed at https://ibn.fm/pcrpA.
For the broader psychedelic medicine industry, Cybin's Nasdaq listing represents another step toward mainstream acceptance and integration of psychedelic compounds into conventional healthcare systems. As clinical trials progress and regulatory pathways become clearer, companies like Cybin are helping establish the infrastructure necessary for these novel treatments to reach patients. The exchange transfer may also influence how other psychedelic medicine companies approach their own capital market strategies as the sector continues to evolve.
